Advertisement
Screener

RELMADA THERAPEUTICS, INC. (RLMD) Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount

2.8 / 5 stars · 68/120 Roast Me

RELMADA THERAPEUTICS, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount

RELMADA THERAPEUTICS, INC. (RLMD) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $7.49 million as of 2025-12-31, per its 10-K filed 2026-03-19.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-03-19

  • 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $7.49M.
  • 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $16.29M.
  • 2024-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $32.00M.
  • 2024-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $39.20M.
Period endShare-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, AmountShare-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount as first filed
2025-12-31$7.49M
10-K · filed 2026-03-19
2024-12-31$16.29M
10-K · filed 2025-03-27
2024-09-30$32.00M
10-Q · filed 2024-11-07
2024-06-30$39.20M
10-Q · filed 2024-08-07
2022-09-30$6.70M
10-Q · filed 2022-11-10
2022-06-30$7.70M
10-Q · filed 2022-08-11
2021-12-31$12.40M
10-K · filed 2022-03-25
2020-12-31$53.50M
10-K · filed 2021-03-24
2020-06-30$103.00K
10-Q · filed 2020-08-12
2020-03-31$116.00K
10-Q · filed 2020-05-15
2019-12-31$54.45M
10-KT · filed 2020-03-26
2019-06-30$3.38M
8-K · filed 2019-10-18
2018-03-31$81.00K
10-Q · filed 2018-05-14
2017-09-30$5.90K
10-Q · filed 2017-11-14
2017-06-30$0.00
10-Q · filed 2018-05-14
$391.29K
10-K · filed 2017-09-28
2016-06-30$1.26M
10-K · filed 2016-09-09
2016-03-31$2.19M
10-Q · filed 2016-05-09
2015-12-31$2.35M
10-Q · filed 2016-02-05
2015-09-30$2.44M
10-Q · filed 2015-11-06
2015-06-30$2.50M
10-K · filed 2015-09-11
2015-03-31$3.13M
10-Q · filed 2015-05-15
2014-12-31$2.09M
10-Q · filed 2015-02-13
2014-09-30$1.86M
10-Q · filed 2014-11-07
2014-06-30$1.76M
10-K · filed 2015-09-11
2013-12-31$589.50K
10-K · filed 2015-09-11
2012-12-31$0.00
10-K · filed 2015-09-11
$68.60K
8-K · filed 2014-05-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63